Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i> Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
These divergent T-cell transcriptional fates suggest that T-cell maintenance and residence may be detrimental to antitumor immunity in the context of neoadjuvant ICB for resectable NSCLC, regardless of KRAS mutation status. Our work provides a basis for future investigations into the mechanisms underpinning prostaglandin E2 signaling and IL-2 signaling as they relate to T-cell immunity to cancer and to divergent clinical outcomes in KRASmut/STK11mut NSCLC treated with neoadjuvant ICB.
Authors
- Zhen Zeng (ORCID: https://orcid.org/0000-0002-3443-0637)
- Samuel Rosner (ORCID: https://orcid.org/0000-0003-4768-3921)
- Lavanya Sivapalan (ORCID: https://orcid.org/0000-0001-8188-7413)
- Rohit Thummalapalli (ORCID: https://orcid.org/0000-0002-8865-0299)
- Brad Presson
- Julie R. Brahmer (ORCID: https://orcid.org/0000-0002-2443-8395)
- Hongkai Ji (ORCID: https://orcid.org/0000-0002-6480-0141)
- Stephen Broderick (ORCID: https://orcid.org/0000-0001-5905-4714)
- Gavin Pereira (ORCID: https://orcid.org/0000-0002-9271-9578)
- Janis M. Taube (ORCID: https://orcid.org/0000-0002-8273-4395)
- Sydney Connor (ORCID: https://orcid.org/0000-0002-0692-8008)
- Joshua E. Reuss (ORCID: https://orcid.org/0000-0002-6401-9080)
- Jonathan Spicer (ORCID: https://orcid.org/0000-0003-2708-1309)
- Khaled Sanber (ORCID: https://orcid.org/0000-0002-8927-9786)
- Valsamo Anagnostou (ORCID: https://orcid.org/0000-0001-9480-3047)
- Kristen Ashley Marrone (ORCID: https://orcid.org/0000-0001-5319-824X)
- Patrick M. Forde (ORCID: https://orcid.org/0000-0001-6925-6344)
- Marianna Zahurak (ORCID: https://orcid.org/0000-0002-5086-6721)
- David R. Jones (ORCID: https://orcid.org/0000-0002-3318-0146)
- Drew M. Pardoll (ORCID: https://orcid.org/0000-0001-6215-1013)
- Julie S. Deutsch (ORCID: https://orcid.org/0000-0002-8040-5205)
- Tricia R. Cottrell (ORCID: https://orcid.org/0000-0003-2952-1830)
- Zhicheng Ji (ORCID: https://orcid.org/0000-0002-9457-4704)
- Kellie N. Smith (ORCID: https://orcid.org/0000-0002-6295-8930)
- Roni Rayes (ORCID: https://orcid.org/0000-0001-7508-020X)
- Jamie E. Chaft (ORCID: https://orcid.org/0000-0002-5838-9982)
- Tianbei Zhang
- Dipika Singh
- Isha Gurumurthy
Institutions
- University of Maryland, Baltimore (US)
- University of Maryland Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Duke University (US)
- Georgetown University (US)
- Queen's University (CA)
- Cornell University (US)
- Johns Hopkins Medicine (US)
- Georgetown University Medical Center (US)
- McGill University Health Centre (CA)
- Queens University (BD)
- Sidney Kimmel Cancer Center (US)
- Vince Lombardi Cancer Clinic (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- McGill University (CA)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2983
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.54
Funders
- Conquer Cancer Foundation
- LUNGevity Foundation
- Bristol-Myers Squibb
- Mark Foundation For Cancer Research
- Swim Across America
- National Institutes of Health